Regulus Therapeutics Inc. (NASDAQ:RGLS) shareholders will have a reason to smile today, with the analysts making…

from Yahoo Finance https://ift.tt/2UF3DhU

Miller Value Partners recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Miller Value Partners Opportunity Equity Fund posted a return of -38.4% for the quarter (net of fees), underperforming its benchmark, the S&P 500 Index which returned -19.6% in the same quarter. You should check out Miller […]

from Yahoo Finance https://ift.tt/30CVj6m

Penny stocks, you either love them or you hate them. One of the obvious draws of these stocks trading for under $5 per share is the ability to get more bang for your buck. And should these bargain priced stocks see their share prices rise by only a small amount, the rewards can be staggering.However, before jumping right into an investment in a penny stock, Wall Street pros advise looking at the bigger picture and considering other factors beyond just the price tag. For some names that fall into this category, you really do get what you pay for, offering little in the way of long-term growth prospects thanks to weak fundamentals, recent headwinds or even large outstanding share counts.Taking the risk into consideration, we used TipRanks’ database to see if we could find compelling penny stocks with bargain price tags. The platform steered us towards three tickers sporting share prices under $5 and “Strong Buy” consensus ratings from the analyst community. Not to mention colossal upside potential is on the table. We’re talking about over 100% here.Veru Inc. (VERU)Operating as an oncology and urology company, Veru develops cutting-edge medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals. At $3.20, several members of the Street believe that its share price presents investors with a unique buying opportunity.Among Veru’s fans is Oppenheimer’s Leland Gershell. The 5-star analyst notes that its VERU-111 candidate is a major component of his bullish thesis, highlighting the fact that it has already demonstrated “compelling efficacy signal in advanced prostate cancer as well as reasonable safety.”Expounding on this, Gershell stated, “As we highlighted last week, biomarker declines, tumor responses, interim durability of benefit, and manageable systemic toxicity seen in dose-escalating study in chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) patients continue to pique our interest in this novel anti-tubulin with a urologist-friendly profile.” The enrollment for Phase 2 is up and running, and the company is planning a Phase 3 trial of the candidate in novel androgen blocker failures.That being said, VERU-111's potential goes even further. Management announced that it would be kicking off a Phase 2 study of the therapy in COVID-19 patients with a high risk of ARDS. Citing the “precedent of anti-viral and anti-inflammatory activity seen with compounds that target the microtubule colchicine binding site”, Gershell is optimistic about VERU-111's use in this indication.Adding to the good news, Gershell sees even more potential catalysts ahead. Veru is gearing up for the Phase 2 program evaluating differentiated GnRH antagonist, VERU-100, in hormone-sensitive prostate cancer next quarter, as well as zuclomiphene's Phase 3 trial for hot flashes in androgen deprivation therapy, which is set to begin late this year. The TADFIN NDA submission could also come at the end of 2020 or early 2021.“With a ~$260 million enterprise value, an intriguing prostate cancer pipeline offering multiple shots on goal, and a growing commercial business supporting R&D, we view VERU as attractive," Gershell concluded.As a result, Gershell rates VERU an Outperform (i.e. Buy) along with a $9 price target. This target conveys his confidence in Veru’s ability to soar 180% in the next year. (To watch Gershell’s track record, click here) All in all, other analysts echo Gershell’s sentiment. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $7 average price target, the upside potential comes in at 118%. (See Veru stock analysis on TipRanks)Surface Oncology (SURF)Up next, we have Surface Oncology, which is developing next generation immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer. Combine a key collaboration, strong cash position and $3.88 share price, and you get the analyst community’s praise.Standing squarely in the bull camp, JonesTrading's Soumit Roy cites several reasons to support his optimistic stance. The company broke the news of its collaboration with Merck on a combination study of Keytruda and SURF’s SRF617 (targeting CD39), with the initial focus being placed on gastric cancer and data set to come in 1H21.“We believe a Merck collaboration positions Surface well as peer’s data start to come out using adenosine pathway inhibitor with IO combo in non-small-cell lung carcinoma (NSCLC),” the 5-star analyst explained. In addition, data looking at the therapy’s efficacy as a single agent and in combination with gemcitabine/Abraxane in pancreatic cancer is slated for release in YE20.Some investors have expressed concern ahead of Arcus’ presentation of data for AB928 combined with carboplatin + pemetrexed + a PD-1 antibody in NSCLC at ASCO. However, Roy believes any positive data should be seen as a good thing for SURF. He added, “We expect early data from Tizona’s CD39i by YE20 and potentially meaningful data from partner Novartis in 3Q/4Q20 (ESMO or Triple meeting) with anti-CD73 antibody to likely to validate Surface’s technology platform – and could put Novartis ahead of AstraZeneca and BMS.”It should be noted that Roy’s focus also remains on SURF’s wholly owned asset, SRF388 (targeting IL-27). Early data evaluating its use in liver and kidney cancer could come in YE20 and 1H21, respectively.“We remain confident in Surface’s differentiated approach — targeting the first enzyme in the ATP/adenosine pathway, CD39, and a novel target, IL-27, to block overexpression of CD39 and T cell inhibiting receptors,” Roy commented. Based on all of the above, it’s no wonder Roy reiterated his Buy recommendation. With a $12 price target, shares could climb 209% higher in the next twelve months. (To watch Roy’s track record, click here) Turning now to the rest of the Street, other analysts are on the same page. With only Buys assigned in the last three months, 3 to be exact, the word on the Street is that SURF is a Strong Buy. Additionally, the $10.50 average price target brings the upside potential to 170%. (See Surface Oncology stock analysis on TipRanks)Anavex Life Sciences (AVXL)Using precision genetic medicine, Anavex Life Sciences wants to develop treatments for severe and devastating neurological disorders. Currently going for $3.61 apiece, some analysts argue that shares appear undervalued.At the beginning of May, the company announced that COVID-19 has had a relatively limited impact on its ongoing clinical trials, with all programs progressing right on track. Top-line data from the Phase 2 study in Parkinson's disease dementia (PDD) is set to be reported in mid-2020. In addition, patient enrollment in both Phase 2 studies in Rett syndrome has already surpassed the 50% mark.Weighing in for Janney Montgomery, analyst Yun Zhong said, “Management plans to make an announcement once the studies complete patient enrollment, and based on our previous discussions with management, we believe the top-line from the Rett syndrome studies could be available in 2020, potentially around the PDD data readout.”On top of this, the genome-wide search for biomarkers in the Phase 2a Alzheimer's disease (AD) study found promising candidates, with four biomarkers that potentially have a significant effect on clinical outcomes, as determined by two efficacy endpoints, MMSE and ADCS-ADL, being identified.“The identification of genomic biomarkers in the Phase 2a study in Alzheimer's disease (AD) was recently published and we believe the biomarkers should benefit the evaluation of ANAVEX 2-73 and other Sigma-1 receptor agonists in many additional CNS indications… These biomarkers can be used to pre-specify patients that are most likely to respond to ANAVEX 2-73 treatment, thereby reducing heterogeneity in AD patients and increasing the probably of success of clinical studies,” Zhong commented.“We remain optimistic that the upcoming clinical catalysts could have a positive impact on the stock and we continue to see strong potential in the company's pipeline,” Zhong concluded.In line with his bullish take, Zhong rates AVXL a Buy along with a $10 price target. Should the target be met, a twelve-month gain of 177% could be in store. (To watch Zhong’s track record, click here) What does the rest of the Street think about AVXL? It turns out that other analysts also have high hopes. 4 Buys and no Holds or Sells have been received in the last three months, so the consensus rating is a Strong Buy. The $11.50 average price target suggests 184% upside potential. (See AVXL stock-price forecast on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

from Yahoo Finance https://ift.tt/2XSlcgC

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

from Yahoo Finance https://ift.tt/2BVpbAl

from Yahoo Finance https://ift.tt/2UB1Dau

J&J Chief Scientific Officer Dr. Paul Stoffels says the vaccine being produced needs a minimum 70% efficacy to be considered successful.

from Yahoo Finance https://ift.tt/37nGXYN

(Bloomberg) — Barstool Sports’ Dave Portnoy had bought just one stock in his life before the quarantine hit. When the country shut down in March, canceling sports and sports betting, the founder of the brash, misogynistic media empire dusted off his old E*Trade account and started day trading.“With the volatility, it is kind of like watching a sports game,” said Portnoy, 43, who started live streaming as “Davey Day Trader Global” to his 1.5 million Twitter followers with the caveat: “I’m not a financial advisor. Don’t trust anything I say about stocks.”Despite the obligatory warning, Portnoy has touted stocks like InspireMD Inc. and Smith & Wesson Brands Inc., while dissing the acumen of Warren Buffett, the world’s fifth-richest person and widely regarded as one of the greatest investors ever. “I’m sure Warren Buffett is a great guy but when it comes to stocks he’s washed up,” Portnoy tweeted Tuesday. “I’m the captain now.”Portnoy and his ilk have been part of one of the greatest rallies in history, adopting as a mantra the online slogan of “stocks only go up!” Market watchers are being forced to ask to what degree retail interest has become a self-fulfilling prophecy in many parts of the market — and what dangers it poses for its sustainability. Thursday’s rout, the deepest in three months, offered a reminder that stocks do, in fact, fall, though equity futures were poised to open higher on Friday.Read more: The Stocks-Only-Go-Up Strategy Falls Into a $2 Trillion DitchMillennials and Gen Zs, the target audience of Barstool content, have long been under-invested in the stock market, said Julian Emanuel, chief equity and derivatives strategist at BTIG LLC.That’s changing. Stuck at home with plenty of free time, government stimulus checks, no sports to bet on and, for better or worse, a figure like Portnoy turning investing into entertainment, more and more young people are wading in for the first time.‘Perfect Storm’“It’s really been a perfect storm,” said Nate Geraci, president of investment-advisory firm the ETF Store, who views Portnoy as the millennial Jim Cramer, the CNBC personality. “Investors are seeing firsthand the thrill of victory, the agony of defeat, and he’s doing it with large sums of money, so I think for younger investors, that’s really enticing.”In January, casino company Penn National Gaming announced it had bought a stake in Barstool for $163 million in cash and stock. Portnoy, who estimates his net worth at more than $100 million, said he’s put $5 million into his day-trading account so far.“I’m a little surprised that it’s become pretty well known within the financial community,” he said. “That’s kind of our target audience regardless of what we’re covering and I think Barstool was popular in those circles to begin with.”Portnoy, a Massachusetts native with a degree in education from the University of Michigan, founded Barstool in 2003 as a weekly newspaper about gambling with the tagline: “By the common man, for the common man.” It has since grown into a media empire synonymous with male frat culture.It has also had its fair share of controversies.ESPN CancelsIn late 2017, ESPN canceled a show hosted by some Barstool personalities following social-media complaints that the website was insulting to women. It has a daily feature with photos of a scantily clad woman called Smokeshow and in the past rated the attractiveness of female teachers who were charged with having sex with their students. The company recently reached a settlement with the National Labor Relations Board to delete tweets in which Portnoy threatened to fire people who talked to union activists.Portnoy’s livestream Davey Day Trader Global, or DDTG, gets hundreds of thousands of viewers on Twitter alone. In the videos, Portnoy mostly half-yells into a microphone as he goes through his portfolio. Sometimes he diverts into stream-of-consciousness asides.“I bought these sunglasses today,” Portnoy said in one video, putting on a pair of reflective aviator sunglasses. “Are these d****bag sunglasses? I think these may be d****bag sunglasses.”DDTG isn’t that different from other Barstool blogs and shows like the raunchy podcast Call Her Daddy. The live streams are interspersed on Portnoy’s timeline with videos of his longer-running show Barstool Pizza Reviews.Scott Nazareth, a 29-year-old day trader from Toronto, said he’s a fan of Portnoy’s videos and believes older investors such as Buffett are missing opportunities in technology and airline stocks.“I kind of make fun of some of these investors,” Nazareth said of Buffett. “They just have a hard time understanding the new normal, the new business models.”With tens and sometimes hundreds of thousands of people watching, there’s some concern that people will take Portnoy’s advice to heart. But Portnoy said he’s made it clear to his viewers not to invest money they can’t afford to lose.“I’m not babysitting our readers,” said Portnoy. “People got to be responsible.”His plugs appear to have had some effect, though. On Wednesday, Portnoy mentioned penny-stock InspireMD, a company that makes products for vascular procedures. The stock had already seen elevated volume since June 2, when the firm announced it would offer an additional 22 million shares. Still, volume surged to an all-time high of 52 million shares after Portnoy’s exhortations.‘Hype Videos’After tweeting a video questioning Buffett’s decision to get out of airlines — where Portnoy doubts the wisdom of “94-year-old guys who live in Nebraska” — volume in JETS, an exchange-traded fund tracking airlines, exploded. The 30-day average volume in the ETF went from $45 million to about $200 million. Portnoy’s video has more than 1 million views.“I’ve never seen a video quite like that outside of hype videos in football,” said Eric Balchunas, an ETF analyst for Bloomberg Intelligence. “The financial industry is not used to that kind of thing.”Buffett, who’s actually just 89, didn’t respond to a request for comment through a spokeswoman.With brokerages offering commission-free trading, “the barriers to entry are essentially zero and the cost to transact is essentially zero,” Emanuel said.Young people, who use their phones for everything, are comfortable dealing with trading apps, and companies like Robinhood Financial appeal to first-time investors with referral promos and free stocks when they sign up.“You look at a platform like Robinhood, in many ways those platforms have game-ified investing,” Geraci said.New AccountsPurdue University student Cameron Coleman, 20, started investing about a month ago after a friend shared his Robinhood referral link. Coleman had been an avid sports better and said he turned to day trading as an alternative during quarantine. He now tracks stocks on two computer monitors he typically uses for gaming and his initial $50 investment was up to $260 as of Tuesday.Robinhood added more than three million funded accounts in the first four months of 2020, and half of customers who opened accounts this year said they were first-time investors, according to Nora Chan, a spokeswoman for the Menlo Park, California-based firm. E*Trade Financial Corp. had 329,000 net new accounts in the first three months of the year, with 260,000 added in March alone, the firm said in its first-quarter earnings statement. That was more than the company’s previous best annual net record.While day trading can be risky and Portnoy might not be the best role model for young investors, Emanuel and Geraci said they think younger investors entering the market is positive for the long-term.“The danger to the accessibility of it is very clear because you are bringing people in who may not be terribly qualified,” Emanuel said. “You learn more when you’re losing.”Coleman said he doubts he would have started investing if it weren’t for the pandemic shutdowns. “I probably would have just continued sports betting because I’m better at that,” he said.Now that he’s begun, Coleman said he plans to continue. “But I’ll switch to a more buy-and-hold strategy.”(Updates with stock futures in fourth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

from Yahoo Finance https://ift.tt/2MPvVlt

Regeneron Pharmaceuticals, Inc (REGN) said Thursday it started the first human clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19.The REGN-COV2 clinical program will consist of four separate study populations: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, individuals that are at high-risk of exposure, such as healthcare workers or first responders, and people with close exposure to a COVID-19 patient. The placebo-controlled trials will be conducted at multiple sites."We have created a unique anti-viral antibody cocktail with the potential both to prevent and treat infection, and also to preempt viral 'escape,' a critical precaution in the midst of an ongoing global pandemic," said George D. Yancopoulos, Co-Founder and Chief Scientific Officer of Regeneron. "REGN-COV2 could have a major impact on public health by slowing spread of the virus and providing a needed treatment for those already sick – and could be available much sooner than a vaccine.”Yancopoulos added that the antibody cocktail approach would also be useful for elderly and immuno-compromised patients, who often do not respond well to vaccines.REGN-COV2's preclinical development and manufacturing has been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA).Shares in Regeneron have surged 62% so far this year. The stock declined 1.7% to $596.18 in early afternoon trading.Five-star analyst Alethia Young at Cantor Fitzgerald this month raised the stock's price target to $624 (3.7% upside potential) from $400 and maintained a Hold rating, saying its drug pipeline faces stiff competition in the generics market.“Potential upside may come from a sustainable commercial COVID-19 franchise, where studies should begin soon,” Young wrote in a note to investors.What does the rest of the Street have to say? The 20 analysts are divided evenly between 10 Buy and 10 Hold ratings adding up to a Moderate Buy consensus. In view of the stock’s recent rally, the analysts’ $573.26 average price target is less optimistic than Young’s indicating a mere 3.5% downside potential in the coming 12 months. (See Regeneron stock analysis on TipRanks).Related News: Emergent Bio Signs Covid-19 Vaccine Manufacturing Deal With AstraZeneca Oxford Biomedica Clinches Manufacturing Deal For AstraZeneca’s Covid-19 Vaccine 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed More recent articles from Smarter Analyst: * Bankrupt Hertz Pops 51% In Pre-Market On $1 Billion Share Sale Plan * Lululemon Drops 5% in Extended Trading After Quarterly Results Miss * Twitter Removes Accounts Linked To China, Russia, Turkey Due To Information Manipulation * Emergent Bio Signs Covid-19 Vaccine Manufacturing Deal With AstraZeneca

from Yahoo Finance https://ift.tt/3hnO9sG

In this article we are going to estimate the intrinsic value of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by taking the…

from Yahoo Finance https://ift.tt/3cX4fGa